Perspective | Open Access

Evidence evaluation in rare disease guidelines: a methodological perspective

Views:  31
Rare Dis Orphan Drugs J 2025;4:[Accepted].
Author Information
Article Notes
Cite This Article

Abstract

This paper examines the methodological challenges of developing rare disease (RD) clinical guidelines and compares the standard GRADE approach with an enhanced methodology tailored to RD constraints. Drawing on ERN working groups, case studies, literature, and discussions from a EURORDIS webinar (April 2024), it identifies strategies to produce evidence-informed recommendations despite limited and heterogeneous data. The enhanced GRADE framework broadens search strategies, integrates qualitative synthesis, real-world evidence, and structured expert/patient input, and uses consensus methods such as Delphi processes and evidence-to-decision frameworks. This enables guideline developers to address sparse data, non-traditional research questions, and variable outcomes while maintaining transparency. For rare diseases, where conventional hierarchies of evidence are often unworkable, this adapted approach provides a flexible, pragmatic, and inclusive pathway. By leveraging registries, expert consensus, and tailored evidence integration, it supports robust, context-sensitive guidelines that remain clinically relevant and improve care for underserved patients.

Keywords

Rare diseases, clinical guidelines, evidence synthesis, methodology

Cite This Article

Bolz-Johnson M, Kenny T, Gaasterland C, Omar MI, Engels M, van Eeghen A, den Uijl I, Irvine W. Evidence evaluation in rare disease guidelines: a methodological perspective. Rare Dis Orphan Drugs J 2025;4:[Accept]. http://dx.doi.org/10.20517/rdodj.2025.29

Copyright

...
© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Cite This Article 0 clicks
Share This Article
Scan the QR code for reading!
See Updates
Hot Topics
rare disease | orphan drug |
Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/